Ribupatide is an investigational injectable peptide for obesity, developed in China by Jiangsu Hengrui Pharmaceuticals under the code HRS9531. Like tirzepatide, the active ingredient in Eli Lilly's Mounjaro and Zepbound, it activates two receptors: the glucagon-like peptide-1 (GLP-1) receptor and the receptor for glucose-dependent insulinotropic polypeptide (GIP). Outside Greater China, Kailera Therapeutics is developing it as KAI-9531.
On November 15, 2026, JAMA published the results of GEMINI-1, Hengrui's Phase 3 obesity trial in China, in which weight fell 17.7% at 48 weeks in the highest-dose group. Hengrui has applied for approval in China. Tirzepatide has been approved by the U.S. Food and Drug Administration (FDA) since 2022, while Drugs@FDA, the agency's database of approved drugs, has no record of ribupatide.
Ribupatide is not the only obesity drug from a Chinese developer. Mazdutide, from Innovent Biologics and Eli Lilly, is already approved in China and activates a different pair of receptors, GLP-1 and glucagon. Mazdutide vs retatrutide vs survodutide covers it.
Where ribupatide came from
Hengrui began testing ribupatide in people in December 2021, in a Phase 1 trial of 90 healthy adults in China. In May 2024, it granted Kailera, a company based in Waltham, Massachusetts, and San Diego, exclusive rights outside Greater China to develop, manufacture and sell its GLP-1 programs, ribupatide among them. FDA's substance registry records ribupatide as the compound's International Nonproprietary Name (INN).
How the two molecules compare
FDA's Global Substance Registration System records ribupatide and tirzepatide as 39-amino-acid chains. The two sequences match at 31 of their 39 positions, including the first 12 and the last 12.
Both carry the same side chain, a 20-carbon fatty diacid joined through a linker to a lysine, at position 14 in ribupatide and position 20 in tirzepatide. Tirzepatide's FDA label says the fatty diacid lets the molecule bind albumin, a blood protein, and prolongs its half-life. That half-life is about 5 to 6 days in people with overweight or obesity, according to the Zepbound label. In ribupatide's Phase 1 trial in healthy adults, its mean half-life after repeated doses was 7 to 8 days.
Retatrutide, Lilly's investigational triple agonist, adds the glucagon receptor to the same two targets. Ribupatide does not, which puts it in tirzepatide's class.
GEMINI-1 results
GEMINI-1 randomized 567 adults in China without diabetes at 55 sites. To enroll, participants needed a body mass index (BMI) of 28 or higher, or 24 or higher with at least one weight-related condition. They received one of three ribupatide doses or placebo for 48 weeks, alongside a lifestyle intervention. Their mean age was 34.4 years and their mean starting weight 93.0 kg (about 205 pounds).
- Weight fell 10.7%, 16.4% and 17.7% from the lowest dose to the highest, against 1.4% with placebo, counting participants whether or not they stayed on treatment.
- Differences from placebo ranged from 9.3 to 16.3 percentage points.
- Gastrointestinal adverse events occurred in 47.9% to 63.1% of participants on ribupatide, rising with dose, against 23.1% on placebo, and 0.7% stopped treatment because of adverse events.
Hengrui and Kailera presented the trial's data at ObesityWeek in November 2025. Their announcement led with 19.2% for the highest dose, an estimate of the effect had every participant stayed on treatment, and reported no plateau in weight loss by week 48.
How GEMINI-1 compares with tirzepatide's trials
The closest tirzepatide trial is SURMOUNT-CN (JAMA, 2024), which Lilly ran in 210 adults in China under the same BMI thresholds, also excluding diabetes. At 52 weeks, weight fell 13.6% and 17.5% with the two doses tested, against 2.3% with placebo, in an analysis of all randomized participants. Participants in the two trials started at similar weights, a mean of 93.0 kg in GEMINI-1 and 91.8 kg in SURMOUNT-CN.
Comparisons with Mounjaro and Zepbound often cite SURMOUNT-1 instead, a 72-week trial. Its 22.5% for tirzepatide's highest dose comes from the analysis that assumes participants stayed on treatment, the same basis as ribupatide's 19.2% at 48 weeks.
As of November 19, 2026, no trial registered on ClinicalTrials.gov compares ribupatide with tirzepatide directly. Separate trials differ in length, population and analysis, so they cannot rank the two compounds, and retatrutide vs tirzepatide vs semaglutide explains why.
Phase 3 programs and approval status
Hengrui applied to China's National Medical Products Administration (NMPA) for approval of ribupatide for long-term weight management in adults, and Hengrui and Kailera said in November 2025 that the application had been accepted. Hengrui's other Phase 3 trials in China, listed on ClinicalTrials.gov, cover:
- Type 2 diabetes, in three trials, one of them a completed comparison with semaglutide in 884 adults.
- Obesity, in a comparison with semaglutide in 572 adults.
- Obstructive sleep apnea with obesity, in two trials.
- Knee osteoarthritis with obesity, in a trial not yet recruiting.
- Atherosclerotic cardiovascular disease, in a trial planned for 9,262 participants.
- An oral tablet form, in adults with overweight or obesity.
Kailera's global program, KaiNETIC, consists of three Phase 3 trials with about 5,000 participants in total, each running 76 weeks. One of them, KaiNETIC-3, includes a semaglutide arm. Kailera said on November 4, 2026, that all three were fully enrolled, with data expected in mid-2028. The KaiNETIC trials test higher doses than GEMINI-1's highest, and a separate Phase 2b trial of still higher doses in about 260 U.S. adults is expected to report in mid-2027. Kailera also plans to start a global Phase 3 program for an oral tablet form of ribupatide in the first half of 2027.
Research listings and tirzepatide prices
PeptideScouter indexes no ribupatide listings.
As of November 19, 2026, 46 of the 47 vendors in our index have tirzepatide in stock. Its median price for a single 30mg vial, the size most of them carry, is $3.27 per mg across 39 vendors, one price per vendor. Price per milligram falls as vials get larger: a median of $5.25 at 10mg across 30 vendors, $3.75 at 20mg across 26 and $2.50 at 60mg across 29. Research vendors often sell tirzepatide under codes such as GLP2, and what GLP-3 means explains the series. Multi-vial kits and non-vial formats are left out of these figures. Definitions are on the methodology page.
Sources
- Zhao and colleagues, JAMA, November 15, 2026: GEMINI-1 results, design and sponsor.
- He and colleagues, Diabetes, Obesity and Metabolism, 2026: ribupatide's Phase 1 trial and half-life.
- Zhao and colleagues, JAMA, 2024: SURMOUNT-CN results.
- FDA Global Substance Registration System, ribupatide and tirzepatide: sequences, side chains and the INN.
- Zepbound prescribing information, DailyMed: the fatty diacid and tirzepatide's half-life.
- Hengrui and Kailera, GEMINI-1 data at ObesityWeek, November 4, 2025: the 19.2% figure, the plateau statement and the accepted application in China.
- Kailera, first participants randomized in KaiNETIC, January 12, 2026: the KaiNETIC design.
- Hengrui and Kailera, ADA 2026 presentations, June 5, 2026: the May 2024 license.
- Kailera, third quarter 2026 results, November 4, 2026: enrollment, expected data and the oral program.
- ClinicalTrials.gov, GEMINI-1, NCT06396429, Phase 1, NCT05152277, KaiNETIC-1, NCT07284875, KaiNETIC-2, NCT07284901, KaiNETIC-3, NCT07284979, Phase 2b, NCT07458269 and SURMOUNT-CN, NCT05024032.
- ClinicalTrials.gov, ribupatide and HRS9531 trial records: Hengrui's Phase 3 trials in China and the absence of a tirzepatide comparison.
- Drugs@FDA: FDA's database of approved drug products.
Prices are as of November 19, 2026, computed from PeptideScouter's own price index. Sources checked November 19, 2026.